659 related articles for article (PubMed ID: 9802745)
1. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
[TBL] [Abstract][Full Text] [Related]
2. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
3. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
4. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
[TBL] [Abstract][Full Text] [Related]
5. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
Larsen J; Hylleberg B; Ng K; Damsbo P
Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.
Gutniak MK; Larsson H; Sanders SW; Juneskans O; Holst JJ; Ahrén B
Diabetes Care; 1997 Dec; 20(12):1874-9. PubMed ID: 9405910
[TBL] [Abstract][Full Text] [Related]
8. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
[TBL] [Abstract][Full Text] [Related]
9. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
[TBL] [Abstract][Full Text] [Related]
12. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients.
Juntti-Berggren L; Pigon J; Karpe F; Hamsten A; Gutniak M; Vignati L; Efendic S
Diabetes Care; 1996 Nov; 19(11):1200-6. PubMed ID: 8908380
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
15. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.
Knop FK; Vilsbøll T; Larsen S; Madsbad S; Holst JJ; Krarup T
Diabetes Care; 2003 Sep; 26(9):2581-7. PubMed ID: 12941722
[TBL] [Abstract][Full Text] [Related]
16. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.
Meier JJ; Weyhe D; Michaely M; Senkal M; Zumtobel V; Nauck MA; Holst JJ; Schmidt WE; Gallwitz B
Crit Care Med; 2004 Mar; 32(3):848-51. PubMed ID: 15090972
[TBL] [Abstract][Full Text] [Related]
17. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
18. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Nauck MA; Kleine N; Orskov C; Holst JJ; Willms B; Creutzfeldt W
Diabetologia; 1993 Aug; 36(8):741-4. PubMed ID: 8405741
[TBL] [Abstract][Full Text] [Related]
19. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
[TBL] [Abstract][Full Text] [Related]
20. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
Kielgast U; Holst JJ; Madsbad S
Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
